BioCentury
ARTICLE | Deals

BioMarin builds on gene therapy momentum with DiNAQOR deal in cardiomyopathy

BioMarin turns to external innovation to build its preclinical gene therapy pipeline

May 5, 2020 1:50 AM UTC
Updated on May 6, 2020 at 7:20 PM UTC

BioMarin’s gene therapy deal with DiNAQOR represents the first step in the company's plans to expand its gene therapy pipeline, while entering what’s becoming a hot cardiovascular indication: cardiomyopathy.

The companies partnered to develop gene therapies for rare cardiomyopathies in a deal that delivers DiNAQOR AG an upfront payment and an investment from BioMarin Pharmaceuticals Inc. (NASDAQ:BMRN) in addition to the potential for milestones and tiered royalties. In exchange, BioMarin received a license to DiNAQOR’s lead program and an option to extend the license to several other programs. Financial terms were not disclosed...

BCIQ Company Profiles

BioMarin Pharmaceutical Inc.